PHARM TOX CONSULTING LIMITEDActive

Company number 07223519Private limited companyIncorporated 2010

Key figures

£1,002,550+15.5%
Net assets 2024/25
+17.1%
Average annual growth 2020/21–2024/25
0500 k1 m1.5 m2020/212021/222022/232023/242024/25

Like most small UK companies, PHARM TOX CONSULTING LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
0500 k1 m1.5 m2020/212021/222022/232023/242024/25
Filed accounts2020/21–2024/25
2020/212021/222022/232023/242024/25
Turnover132,029————
Profit for the year76,346————
Total assets556,238641,317759,959917,2221,064,660
Total liabilities23,65923,41128,02749,32362,110
Net assets / total equity532,579617,906731,932867,8991,002,550
Average number of employees22222
Average pay (per year)7,691————

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: PHARM TOX CONSULTING LIMITED

Company

PHARM TOX CONSULTING LIMITED is a private limited company registered with Companies House under company number 07223519. It was incorporated on 14 Apr 2010. Its status is active. The registered office is in Bury st. edmunds (IP28). Its nature of business (SIC 2007) is other research and experimental development on natural sciences and engineering (72190).

Accounts

The latest accounts in the database are for 2024/25 (period ending 30 Apr 2025); the company files micro-entity accounts. Net assets were £1,002,550, up 15.5% on the previous year. Total assets were £1,064,660 and total liabilities £62,110. The company had an average of 2 employees. Figures are available for 5 financial years (2020/21–2024/25).

Control and charges

2 persons with significant control are registered.

Filing deadlines

The next accounts are due by 31 Jan 2027. The next confirmation statement is due by 24 Feb 2027.